C4 THERAPEUTICS INC (CCCC) Stock Income Statement
NASDAQ:CCCC - Nasdaq - US12529R1077 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 39.78M | 35.58M | 20.76M | 31.10M | 45.79M | |||
| Operating Expenses | 156.34M | 152.76M | 159.79M | 160.63M | 127.92M | |||
| Research and Development | 115.18M | 110.64M | 117.71M | 117.84M | 94.67M | |||
| Selling, General, and Administrative Expenses | 41.17M | 42.12M | 42.08M | 42.79M | 33.25M | |||
| Operating Income | -116.56M | -117.18M | -139.03M | -129.53M | -82.13M | |||
| Interest Income/Expense | 13.41M | 14.43M | 8.44M | 1.36M | -1.76M | |||
| Other Income/Expense | N/A | N/A | N/A | N/A | N/A | |||
| Non Recurring Items | 0.00 | -2.44M | -621.00K | N/A | N/A | |||
| Income Before Taxes | -103.15M | -105.19M | -131.21M | -128.18M | -83.89M | |||
| Income Tax | N/A | 131.00K | 1.28M | N/A | 0.00 | |||
| Net Income | -103.28M | -105.32M | -132.49M | -128.18M | -83.89M | |||
| EBITDA | -114.73M | -115.36M | -137.15M | -127.85M | -80.64M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.47 | -1.52 | -2.67 | -2.62 | -1.82 | |||
| Non GAAP EPS | -1.47 | -1.51 | -2.66 | -2.63 | -1.82 | |||
| Statistics | ||||||||
| Profit Margin | -259.60% | -295.96% | -638.34% | -412.15% | -183.21% | |||
| Operating Profit Margin | -292.99% | -329.30% | -669.84% | -416.50% | -179.36% | |||
All data in USD